Hernández-Breijo, Borja http://orcid.org/0000-0002-2630-3312
Navarro-Compán, Victoria
Plasencia-Rodríguez, Chamaida
Parodis, Ioannis
Gehin, Johanna E.
Martínez-Feito, Ana
Novella-Navarro, Marta
Mezcua, Araceli
Warren, David J.
Nozal, Pilar
Pascual-Salcedo, Dora
Balsa, Alejandro
Article History
Received: 20 November 2020
Accepted: 24 May 2021
First Online: 2 June 2021
Competing interests
: V.N-C reports speaker fees and grants from Abbvie, Janssen, Lilly, MSD, Novartis, Pfizer and UCB during the conduct of the study. CP-R has received research grants/honoraria from AbbVie, Lilly, Novartis, Pfizer, Sanofi, Biogen and UCB. I.P. has received research funding from GlaxoSmithKline and Elli Lilly and Company, and honoraria from Gilead Sciences, GlaxoSmithKline and Novartis; all of the above are unrelated to this work. JE.G reports speaker fees from Roche. D.P-S reports speaker fees and grants from Abbvie, Grifols, Menarini, Novartis, Pfizer and Takeda during the conduct of the study. A.B reports grants, consultancies and speaker fees from Abbvie, BMS, Nordic, Novartis, Pfizer, Sandoz, Sanofi, Roche and UCB during the conduct of the study. The other authors declare that they have no competing interests.